Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and Mass Balance of Tanimilast in Healthy Volunteers
NCT04756960Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area Under the Curve from Time 0 to Last Quantifiable Concentration (IV), Maximum Observed Plasma Concentration (IV) and 15 more. Started Mar 2021; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04756960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756960.